共 40 条
- [31] A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trialLANCET INFECTIOUS DISEASES, 2018, 18 (01): : 58 - 67Sricharoenchai, SirintipSirivichayakul, ChukiatChokephaibulkit, KulkanyaPitisuttithum, PunneeDhitavat, JittimaPitisuthitham, AromPhongsamart, WanatpreeyaBoonnak, KobpornLapphra, KeswadeeSabmee, YupaWittawatmongkol, OrasriChinwangso, PailinrutPoredi, Indrajeet KumarPetre, JeanPham Hong ThaiViviani, Simonetta
- [32] Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialLANCET, 2011, 378 (9787): : 229 - 237Cohen, Calvin J.Andrade-Villanueva, JaimeClotet, BonaventuraFourie, JanJohnson, Margaret A.Ruxrungtham, KiatWu, HaoZorrilla, CarmenCrauwels, HertaRimsky, Laurence T.Vanveggel, SimonBoven, Katia
- [33] Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialLANCET, 2020, 396 (10246): : 239 - 254Mayer, Kenneth H.Molina, Jean-MichelThompson, Melanie A.Anderson, Peter L.Mounzer, Karam C.De Wet, Joss J.DeJesus, EdwinJessen, HeikoGrant, Robert M.Ruane, Peter J.Wong, PamelaEbrahimi, RaminZhong, LijieMathias, AnitaCallebaut, ChristianCollins, Sean E.Das, MoupaliMcCallister, ScottBrainard, Diana M.Brinson, CynthiaClarke, AmandaColl, PepPost, Frank A.Hare, C. Bradley
- [34] A phase 3, multicentre, randomised, double-blind, non-inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) in patients on haemodialysis (HD)NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V260 - V260Locatelli, FVilla, GBacks, WDel Pino, MD
- [35] A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trialLANCET, 2018, 391 (10119): : 431 - 440de Winter, Robbert J.Katagiri, YukiAsano, TakuMilewski, Krzysztof P.Lurz, PhilippBuszman, PawelJessurun, Gillian A. J.Koch, Karel T.Troquay, Roland P. T.Hamer, Bas J. B.Ophuis, Ton OudeWoehrle, JochenWyderka, RafalCayla, GuillaumeHofma, Sjoerd H.Levesque, SebastienZurakowski, AleksanderFischer, DieterKosmider, MaciejGoube, PascalArkenbout, E. KarinNoutsias, MichelFerrari, Markus W.Onuma, YoshinobuWijns, WilliamSerruys, Patrick W.
- [36] Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trialLANCET ONCOLOGY, 2025, 26 (01): : 37 - 50Meattini, IcroDe Santis, Maria CarmenVisani, LucaScorsetti, MartaFozza, AlessandraMeduri, BrunoDe Rose, FiorenzaBonzano, ElisabettaPrisco, AgneseMasiello, ValeriaLa Rocca, ElianaSpoto, RuggeroBecherini, CarlottaBlandino, GladysMoscetti, LucaRay Colciago, RiccardoAudisio, Riccardo A.Brain, EtienneCaini, SaverioHamaker, MarijeKaidar-Person, OritLambertini, MatteoMarrazzo, LiviaSaieva, CalogeroSpanic, TanjaVratislav, StrnadWheelwright, SallyPoortmans, Philip M. P.Livi, LorenzoEUROPA Trial Investigators
- [37] Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in CameroonLANCET HIV, 2020, 7 (10): : E677 - E687Calmy, AlexandraSanchez, Tamara TovarKouanfack, CharlesMpoudi-Etame, MireilleLeroy, SandrinePerrineau, SegoleneWandji, Martial LantcheTata, Darius TetsaBassega, Pierette OmgbaBwenda, Therese AbongVarloteaux, MarieTongo, MarcelMpoudi-Ngole, EitelMontoyo, AliceMercier, NoemieLeMoing, VincentPeeters, MartineReynes, Jacques
- [38] Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trialLANCET ONCOLOGY, 2024, 25 (02): : 246 - 254Bajpai, JyotiKapu, VenkateshRath, SushmitaKumar, SravanSekar, AnbarasanPatil, PriyankaSiddiqui, AltafAnne, SrikanthPawar, AkashSrinivas, SujayBhargava, PrabhatGulia, SeemaNoronha, VanitaJoshi, AmitPrabhash, KumarBanavali, ShripadSarin, RajivBadwe, RajendraGupta, Sudeep
- [39] Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trialLANCET HIV, 2018, 5 (01): : E23 - E34Orkin, ChloeMolina, Jean-MichelNegredo, EugeniaArribas, Jose R.Gathe, JosephEron, Joseph J.Van Landuyt, ErikaLathouwers, ErkkiHufkens, VeerlePetrovic, RomanaVanveggel, SimonOpsomer, Magda
- [40] PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancerHEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (17) : 1 - +Mehanna, HishamMcConkey, Chris C.Rahman, Joy K.Wong, Wai-LupSmith, Alison F.Nutting, ChrisHartley, Andrew G. J.Hall, PeterHulme, ClairePatel, Dharmesh K.von Zeidler, Sandra VentorinRobinson, MaxSanghera, BalFresco, LydiaDunn, Janet A.